Research

A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm


Reference:

Cordery, S. F., Taverner, A., Ridzwan, I. E., Guy, R. H., Delgado-Charro, M. B., Husbands, S. M. and Bailey, C. P., 2014. A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm. Addiction Biology, 19 (4), pp. 575-586.

Related documents:

[img]
Preview
PDF (revised paper CPB 21 Oct - submitted - authors accepted version) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (972kB) | Preview

    Official URL:

    http://dx.doi.org/10.1111/adb.12020

    Related URLs:

    Abstract

    Concurrent use of cocaine and heroin is a major public health issue with no effective relapse prevention treatment currently available. To this purpose, a combination of buprenorphine and naltrexone, a mixed very-low efficacy mu-opioid receptor agonist/kappa-opioid receptor antagonist/nociceptin receptor agonist, was investigated. The tail-withdrawal and the conditioned place preference (CPP) assays in adult Sprague Dawley rats were used to show that naltrexone dose-dependently blocked the mu-opioid receptor agonism of buprenorphine. Furthermore, in the CPP assay, a combination of 0.3 mg/kg buprenorphine and 3.0 mg/kg naltrexone was aversive. A combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone was neither rewarding nor aversive, but still possessed mu-opioid receptor antagonist properties. In the CPP extinction and reinstatement method, a combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone completely blocked drug-primed reinstatement in cocaine-conditioned rats (conditioned with 3 mg/kg cocaine, drug prime was 3 mg/kg cocaine) and attenuated drug-primed reinstatement in morphine-conditioned rats (conditioned with 5 mg/kg morphine, drug prime was 1.25 mg/kg morphine). These data add to the growing evidence that a buprenorphine/naltrexone combination may be protective against relapse in a polydrug abuse situation.

    Details

    Item Type Articles
    CreatorsCordery, S. F., Taverner, A., Ridzwan, I. E., Guy, R. H., Delgado-Charro, M. B., Husbands, S. M. and Bailey, C. P.
    DOI10.1111/adb.12020
    Related URLs
    URLURL Type
    http://www.scopus.com/inward/record.url?scp=84904264050&partnerID=8YFLogxKUNSPECIFIED
    DepartmentsFaculty of Science > Pharmacy & Pharmacology
    Research CentresCentre for Sustainable Chemical Technologies
    Centre for Mathematical Biology
    EPSRC Centre for Doctoral Training in Statistical Mathematics (SAMBa)
    RefereedYes
    StatusPublished
    ID Code32853

    Export

    Actions (login required)

    View Item

    Document Downloads

    More statistics for this item...